BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 7987990)

  • 1. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaƫr JY
    Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY; Mistry P; Kelland LR; Abel G; Harrap KR
    Br J Cancer; 1992 Dec; 66(6):1109-15. PubMed ID: 1457352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ; Abel G; Kelland LR; Harrap KR
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
    Ferguson PJ; Currie C; Vincent MD
    Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
    Sharp SY; Rowlands MG; Jarman M; Kelland LR
    Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells.
    Kikkawa F; Kojima M; Oguchi H; Maeda O; Ishikawa H; Tamakoshi K; Mizuno K; Kawai M; Suganuma N; Tomoda Y
    Anticancer Res; 1993; 13(4):891-6. PubMed ID: 8352556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
    Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Kelland LR; Abel G
    Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.